Dylann Bailey

OMS906, a MASP-3 inhibitor, demonstrated clinical efficacy in a proof-of-concept study for patients with paroxysmal nocturnal hemoglobinuria, according to an interim analysis presented at the 2023 EHA Congress.

Epcoritamab plus rituximab/lenalidomide demonstrated antitumor activity in patients with relapsed/refractory follicular lymphoma, including those with high-risk features.

Ruxolitinib elicited higher responses at day 28 compared with best available therapy in most cytopenia-based subgroups and had durable responses at day 56, according to a post hoc analysis of the REACH2 trial.

Long-term outcomes did not differ among de novo late acute graft-vs-host disease and classic acute graft-vs-host disease, showing they should be treated the same way.

Patients with hepatocellular carcinoma treated from 2018 to 2021 experienced better efficacy vs patients treated from 2008 to 2018, according to a real-world study.

Salvage chemotherapy after lintuzumab-Ac225 showed promising early efficacy results in patients with relapsed/refractory acute myeloid leukemia by eliminating residual leukemia cells.

Survival advantage was shown in a phase 3 study of neoadjuvant chemotherapy/carboplatin in patient with triple negative breast cancer.

Combinations of the BCL2 inhibitor venetoclax with hypomethylating agents are undergoing investigation to determine benefit in high-risk myelodysplastic syndrome.

Adjuvant treatment with canakinumab did not meet the disease-free survival primary end point in patients with completely resected non–small cell lung cancer versus placebo, nor did subgroup analyses show statistically significant differences in DFS, according to results from the phase 3 CANOPY-A trial presented at ESMO Congress 2022.

At the 2022 ESMO Congress, results from the NICHE-2 trial showed neoadjuvant immunotherapy in patients with mismatch repair deficient colon cancer had notable responses to the therapy well above neoadjuvant chemotherapy.

Updated analysis results of from the IKEMA showed improvement in the depth of response to isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma.

In patients enrolled in the phase 1b portion of the KRYSTAL-1 trial who received adagrasib, the intracranial objective response rate was 32%.

Three-year follow-up of the CheckMate 9LA trial shows continued survival benefit to nivolumab/ipilimumab plus 2 cycles of chemotherapy in patients with metastatic non–small cell lung cancer.

Enzalutamide showed continued overall survival benefit in patients with metastatic hormone-sensitive prostate cancer after over 5 years of follow-up.

BTX-1188 could prevent systemic inflammatory dose-limiting toxicities that are usually attributed to pure GSPT1 degradation due to its immunomodulatory properties from the IKZF1/3 degradation.

The combination of tislelizumab plus nab-paclitaxel demonstrated benefit and a tolerable safety profile in patients with high-risk non–muscle invasive bladder cancer.

Tislelizumab plus nab-paclitaxel as neoadjuvant treatment demonstrated benefit with a high rate of pathologic complete response in patients with muscle-invasive bladder cancer.

JSP191 combined with fludarabine, and low-dose total body radiation demonstrated facilitation of full donor myeloid chimerism, clearing of minimal residual disease, and a well-tolerated safety profile in older patients with myelodysplastic syndrome/acute myeloid leukemia receiving non-myeloablative allogenic hematopoietic cell transplantation.

Based on the encouraging efficacy signals of SOT101 plus pembrolizumab in these heavily pretreated patients with advanced solid tumors in the AURELIO-03 study, the AURELIO-04 trial is planned.

Regarding cutaneous squamous cell carcinoma, what is most exciting is the remarkable complete response rate, up to almost 50%, according Jiaxin Niu, MD.

In a final overall survival analysis of CheckMate 9ER, investigators saw a continued survival benefit with first-line nivolumab plus cabozantinib compared with sunitinib in the intention-to-treat patients with untreated clear cell metastatic or advanced renal cell carcinoma.

In the phase 3 KEYNOTE-394 trial, pembrolizumab and best supportive care prolongs survival in patients.

Compared with ibrutinib, acalabrutinib demonstrates less toxicity burden In CLL.

In a randomized phase 3 trial, acalabrutinib plus venetoclax versus obinutuzumab plus venetoclax will be investigated for efficacy and safety with a noninferiority design in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic leukemia.

In the phase 2 I-SPY 2 platform trial, receipt of targeted neoadjuvant chemotherapy did not appear to be based on race.

Investigators are looking into newer ways of using hypomethylating agents to treat patients with low-risk and high-risk myelodysplastic syndrome.

Olatoyosi Sobulo Odenike, MD, explored the risk factors for evolution to MPN AP/blast phase, outcomes for current treatment methods, and potential targeted therapies during a presentation.

Adapting therapy to patients using the available criteria may be the key to future treatment in patients with polycythemia vera.

Zanubrutinib has been approved by the FDA to treat adult patients with Waldenström macroglobulinemia.

In the wake of immunotherapy combinations becoming available in breast cancer, including triple-negative breast cancer, the Society for Immunotherapy of Cancer has published clinical practice guidelines for physicians treating in this setting.